Background: We aimed to analyze serum neurofilament light chain (sNfL) levels in patients undergoing endovascular therapy (EVT) for anterior circulation large vessel occlusion (acLVO).
Methods: Prospective study of consecutive patients with acLVO receiving EVT (12/2020-01/2021). sNfL was serially measured prior to and at 30-min, 6-h, 12-h, 24-h, 48-h and 7-days following EVT. ANOVA and Spearman correlation were run to assess sNfL levels (ie, absolute values) and ΔsNfL levels (ie, absolute values subtracted by baseline value) and their association with clinical (ie, NIHSS), imaging (ie, ASPECTS) surrogates of stroke severity as well as functional outcome (ie, mRS) at 90-days.
Results: 175 sNfL samples were retrieved from 25 patients. While there were no differences among serial sNfL levels in the first 12-h post-EVT, a constant increase was observed afterwards (maximum day 7, median: 383 [IQR, 209-907] pg/mL, p < 0.001). ΔsNfL showed a constant increase from 30-min measurement onwards peaking after 7 days (median 363.5 [IQR, 114.3-851.1] pg/mL). sNfL levels at 7 days correlated with ASPECTS post-EVT (r = -0.59, p < 0.001), NIHSS at discharge (r = -0.50, p = 0.011) and mRS at 90-days (r = 0.45, p = 0.027).
Conclusions: Serum NFL may complement established clinical and imaging predictors of treatment response and functional outcome in stroke patients undergoing EVT for acLVO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2021.118063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world data of serum neurofilament light chain in a large cohort of Egyptian multiple sclerosis patients: Hospital-based study.
Mult Scler Relat Disord
January 2025
Department of Neurology and Psychiatry, Faculty of Medicine Assiut University, Assiut, Egypt. Electronic address:
Background: Serum neurofilament light chain (sNFL) is a promising biomarker for neuroaxonal injury in multiple sclerosis (MS). Traditional clinical and radiological examinations often fail to capture the underlying neurodegeneration, particularly in the absence of clinical relapses or gadolinium-enhanced lesions. This study aims to assess sNFL levels in real-world MS patients who have no evidence of activity, to evaluate the potential of sNFL as a biomarker for smoldering-associated worsening (SAW).
View Article and Find Full Text PDFContribution of Blood Biomarkers to Multiple Sclerosis Diagnosis.
Neurol Neuroimmunol Neuroinflamm
March 2025
Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), chitinase-3-like 1 (sCHI3L1), and the immune responses to the Epstein-Barr virus-encoded nuclear antigen 1 to current MS diagnostic criteria.
Methods: In this multicentric study, we selected patients from 2 prospective cohorts presenting a clinically isolated syndrome (CIS).
Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy.
J Neurol Sci
January 2025
Neuromuscular Diseases Unit, Department of Neurology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain; Department de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Background: The development of new biomarkers is essential to improve diagnostic accuracy and guide treatment decisions in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The aim of this study was to investigate the utility of the serum neurofilament light chain (sNfL) level as a marker for disability and response to immunomodulatory treatment in patients with CIDP.
Methods: This prospective, single-center, observational study included 38 patients with CIDP: 19 treatment-naive (CIDP-I) patients assessed before and after the initiation of immunomodulatory therapy and 19 stable patients on maintenance immunoglobulins (CIDP-M).
Prognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study.
Brain Behav
January 2025
Department of Neurology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Background: The diagnostic and prognostic values of serum neurofilament light chain (sNfL), in comparison to cerebrospinal fluid (CSF) neurofilament light chain (cNfL), and other clinical parameters in amyotrophic lateral sclerosis (ALS) at the time of diagnosis remain elusive.
Methods: We examine paired serum and CSF samples from 80 ALS patients and 21 control subjects, all obtained at the time of diagnosis. Additional serum samples were collected from 51 other ALS patients.
Evaluating neurofilament light chain serum levels as a diagnostic marker for Lyme neuroborreliosis.
Ther Adv Neurol Disord
January 2025
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Background: Serum neurofilament light chain (sNfL) is a biomarker for neuro-axonal injury.
Objectives: To assess sNfL's utility as a diagnostic marker for Lyme neuroborreliosis (LNB).
Methods: We compared serum and CSF NfL levels in LNB patients and age-matched controls.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!